"Has anyone simply asked Don about the timetable to release the Kidney and Dementia data?"

Cabel asked IR and got a pretty clear response:

"Any violation of embargo policies set by AHA and certain publications will result in removal of any presentation at this venue and prevent us from being published. An example of a violation would be to present BETonMACE data earlier including at ASN."

Given this, it is likely that the kidney results will form part of the AHA presentation (and possibly an accompanying publication).  If not, I would expect a topline announcement and publication of the kidney results in short order after AHA because the kidney results come in a clinically relevant form (i.e. eGFR results are used directly in the management of patients).  Success (or failure) here is a big deal.

With respect to cognition, the company has made this clear through their provision of the titles of presentations to be given at CTAD in December and Bear has done his usual meticulous job of spoonfeeding that info to members of this forum:

"Clinical Trials on Alzheimer's Disease (CTAD): December 4-7, 2019; San Diego, CA. Two presentations in the final program on Thursday Dec 5th during the symposium on "Epigenetics and the BET-system in vascular dementia, Alzheimer’s disease and mixed dementia – the problem and potential remedies." One of them is the BETonMACE cognition sub-study. A top-line statement on the cognition sub-study results could come ahead of CTAD.

PRESENTER 3: The epigenetic inhibitor APABETALONE corrects pathophysiological brain endothelial and microglial cell activation that contributes to neurodegenerative disease Ewelina Kulikowski, SVP Research and Development, Resverlogix Corporation, Calgary, Canada

PRESENTER 4: Epigenetics, the BET-system, Alzheimer’s Disease and Vascular Cognitive Impairment; The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA."

Our problem is that:  "The waiting is the hardest part..."

Jupe